1. Sun Pharma to Acquire Checkpoint Therapeutics for US$355 Million (over ?3000 crore).
2. Zydus Lifesciences Limited has entered into exclusive negotiations to purchase a controlling 85.6% stake in France-based Amplitude Surgical SA - an entity specialising in high-quality lower-limb orthopaedic products and solutions - for a deal valued at €256.8 Million (over ?2,400 crore).
3. Biocon’s subsidiary Syngene acquires US biologics facility from Emergent for US$36.5 Million (~?312 crore).
4. Senores Pharma acquires 14 ANDAs from Dr. Reddy's.
5. Zydus with Gates Foundation to develop Typhoid-Shigella vaccine.
6. AdjuTec Pharma to advance AMR Candidate in Preclinical Stage with Venus Remedies.
7. Dr. Reddy’s partners with Bio-Thera for biosimilar commercialization in South Asia.
8. Jazz Pharmaceuticals to buy Chimerix for US$935 Million.
9. AbbVie enters obesity race with US$350 Million upfront for Gubra’s Amylin.
10. Novo Nordisk is expanding its pipeline of obesity medicines, announcing Monday it will pay United Laboratories US$200 Million upfront to license an experimental "triple agonist" weight loss shot.
11. Latigo receives US$150 Million to get non-opioid data to compete with Vertex in acute pain.
12. Novartis licenses Kyorin’s preclinical chronic hives candidate for US$55Million upfront.
13. Valo Therapeutics announces EUR 19 Million of investment funding to clinically develop its innovative immune therapy for cancer.
14. OncoZenge in licensing agreement with Molteni Farmaceutici for the commercialization of BupiZenge in Europe.

1. New Client Win: California company with Phase 3 stage small molecule eye drop to treat pre-surgical cataract (typically patients under 72 years of age).
2. Aagami Founder Dinesh Jain successfully concluded DCAT Week(March 17-20) in New York City, engaging in 25 one-on-one meetings with CEOs and decision makers to foster strategic partnerships, for Aagami and its clients.
3. Aagami to attend BIO International Convention in Boston (June 16-19). Partnering platform for meetings open week of April 7^th. 

For Partnering/Licensing/ Co-development:

1. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may be obtained. 
2. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too. 
3. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule eye drop to treat pre-surgical cataract (typically patients under 72 years of age).
4. Seeking Acquisition /JV – Clinical stage Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia [Second Human Trial (n=30) ongoing in AU]. Now Leveraging latest in AI.
5. Seeking Partnering: Nose to brain Delivery using known small molecules targeting orphan diseases such as FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – For 1) Depression and ALS 2) Anti-Obesity. Need Partnering/Investment to enter Phase 1 trials.

For Acquisition:

1. Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.
2. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics.
3. US IP/Asset sale: A small molecule NSAID combination for Migraine and other indications using 505(b)(2).
4. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). Now Leveraging the Latest in AI.

Seeking Investment:

1. Market Ready Nutra portfolio of US client leveraging the latest in AI; Offering stake for up to $25 Million investment, and or regional/global rights.
2. Human-derived, chimeric therapeutic peptide. Phase 2b stage in Atopic Dermatitis. Novel well understood MoA. Strong patent position supportive of various multi-billion- dollar markets and multiple applications, seeking $10 Million.
3. Nose to brain Delivery using known small molecules targeting orphan diseases such as  FrontoTemporal Dementia (FTD) [Orphan Drug Designation Granted by US FDA], Alzheimer’s disease, Parkinson's disease, and Dementia with Lewy Bodies. Two new assets added – 1. For Depression and ALS 2. Anti-Obesity. Presently seek $9 Million.
4. Engineering Therapeutics to Block Pathogenic Autoantibodies: Need investment for:
1. GLP-tox studies
2. First-in-human trials
3. Phase II ready Series A raise

Specialized Services

1. Oligonucleotide and peptides specialist Japanese CDMO for one stop solution to accelerate R&D. 40+ PhDs, Best in quality, excellent customer service and reasonable cost.

Hope you found the content useful. We welcome your feedback and queries.